ArticleAdvanced healthcare materials2025
Programmed Aggregation of Lipidated Nitrobenzoselenadiazole as a Photo-Activatable Pyroptosis Inducer.
Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Programmed Aggregation of Lipidated Nitrobenzoselenadiazole as a Photo-Activatable Pyroptosis Inducer.Advanced healthcare materials · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Bioactive photosensitizers in photodynamic therapy (PDT) have emerged as a promising therapeutic approach for tumor treatment. However, the aggregation of photosensitizers in aqueous solutions could hinder their efficacy, leading to reduced generation of reactive oxygen species (ROS) in biological systems and lower therapeutic effectiveness. For the first time, this work discloses a programmed aggregation system based on the nitrobenzoselenadiazole (NBSD) scaffold with varying alkyl chain lengths (C1, C3, and C8), focusing on their potential as photo-activable pyroptosis inducers. This study underscores the significance of molecular design in developing effective photosensitizers and marks a new era in controlling molecular packing and photophysical properties. Among the candidates, NBSD-NOc exhibits superior performances in several areas: (i) aggregation-enhanced PDT effect, (ii) high cellular uptake, (iii) induction of programmed cell death, (iv) implantable properties, and (v) high biocompatibility. Overall, this work highlights the critical balance between aggregation patterns and photophysical properties, presenting a promising strategy for post-surgical management using implantable photosensitizers to address the potential challenge of tumor recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.